SCHEMBL4154872

SCHEMBL4154872

COc1cc2c(Oc3ccc(NC(=O)Nc4ccc(C(F)(F)F)cc4)cc3F)ccnc2cc1OCCC[C@@H](N)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MET P08581 8/20 0.65
FLT3 P36888 11/20 0.59
PDGFRA P16234 1/20 0.58
KDR P35968 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4154891 1.00 MET (0.65) METFLT3PDGFRAKDR
SCHEMBL2063314 0.97 MET (0.65) METFLT3PDGFRAKDR
SCHEMBL2063322 0.97 MET (0.65) METFLT3PDGFRAKDR
SCHEMBL2063183 0.91 MET (0.63) METPDGFRAKDR
SCHEMBL2063179 0.91 MET (0.63) METPDGFRAKDR
SCHEMBL2063776 0.91 MET (0.63) METPDGFRAKDR
SCHEMBL2063495 0.88 MET (0.58) METFLT3PDGFRAKDR
SCHEMBL2063460 0.88 MET (0.58) METFLT3PDGFRAKDR
SCHEMBL2063492 0.88 MET (0.58) METFLT3PDGFRAKDR
SCHEMBL2062926 0.88 KDR (0.62) METPDGFRAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CDK1, AURKC, CSNK1G3 MET 1888/4885FLT3 578/4885PDGFRA 3858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.